Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema,

Daily brief: Novartis spends big on ezcema,

Kite invests in Gadeta’s gamma delta T cell receptors. Gilead acquired Kite last year for its leadership in cutting edge CAR-T drugs – and the now approved Yescarta – and now ... Alessandro Riva, MD, Gilead's executive vice president, Oncology

Latest news

More from news
Approximately 131 fully matching, plus 313 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Gilead’s success with its curative Hep C portfolio had ultimately led to a diminishing population of target patients and played havoc with its revenues. ... Sanofi’s Lantus (-18.8%), Amgen’s Enbrel (-10.8%) and Gilead’s Harvoni (-48.5%) are among

  • Academic-industry collaboration in the era of big data Academic-industry collaboration in the era of big data

    Noteworthy international examples to this direction include Pfizer’s collaboration with seven New York medical institutes and eight Boston research institutions, Gilead’s with Yale University, AstraZeneca’s with the National

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... In this case Gilead’s cash mountain and the pressing need for a deal outweighed the uncertainty

  • Deal Watch - May 2017 Deal Watch - May 2017

    More recent data reported in FiercePharma (1. st. May) shows Amgen has cash overseas of $34bn, Gilead $27bn and Merck &Co $22bn.

  • When science is not enough When science is not enough

    Witness Gilead’s hepatitis C drug sovaldi (sofosbuvir) which has glowing efficacy results yet is having a troubled transition into the market place.

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics